A detailed history of United Capital Financial Advisers, LLC transactions in Incyte Corp stock. As of the latest transaction made, United Capital Financial Advisers, LLC holds 6,683 shares of INCY stock, worth $460,057. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,683
Previous 7,028 4.91%
Holding current value
$460,057
Previous $426,000 3.52%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$57.33 - $68.61 $19,778 - $23,670
-345 Reduced 4.91%
6,683 $441,000
Q2 2024

Aug 14, 2024

BUY
$51.18 - $63.75 $54,762 - $68,212
1,070 Added 17.96%
7,028 $426,000
Q1 2024

May 15, 2024

BUY
$56.55 - $66.59 $28,840 - $33,960
510 Added 9.36%
5,958 $339,000
Q4 2023

Feb 14, 2024

BUY
$52.16 - $64.19 $284,167 - $349,707
5,448 New
5,448 $342,000
Q2 2023

Aug 14, 2023

SELL
$60.95 - $75.51 $105,748 - $131,009
-1,735 Reduced 28.56%
4,340 $270,000
Q1 2023

Aug 14, 2023

BUY
$70.23 - $86.01 $121,849 - $149,227
1,735 Added 39.98%
6,075 $439,000
Q1 2023

May 15, 2023

SELL
$70.23 - $86.01 $233,936 - $286,499
-3,331 Reduced 35.41%
6,075 $439,000
Q4 2022

Feb 14, 2023

SELL
$67.18 - $84.11 $6,382 - $7,990
-95 Reduced 1.0%
9,406 $755,000
Q3 2022

Nov 14, 2022

SELL
$66.18 - $82.86 $8,669 - $10,854
-131 Reduced 1.36%
9,501 $633,000
Q2 2022

Aug 11, 2022

BUY
$66.18 - $83.18 $463 - $582
7 Added 0.07%
9,632 $732,000
Q1 2022

May 16, 2022

SELL
$66.02 - $79.71 $23,503 - $28,376
-356 Reduced 3.57%
9,625 $764,000
Q4 2021

Feb 14, 2022

SELL
$63.34 - $74.11 $126,806 - $148,368
-2,002 Reduced 16.71%
9,981 $733,000
Q3 2021

Nov 15, 2021

SELL
$68.67 - $84.02 $123,125 - $150,647
-1,793 Reduced 13.02%
11,983 $824,000
Q2 2021

Aug 13, 2021

SELL
$79.87 - $87.53 $58,624 - $64,247
-734 Reduced 5.06%
13,776 $1.16 Million
Q1 2021

May 14, 2021

BUY
$76.02 - $100.5 $59,143 - $78,189
778 Added 5.67%
14,510 $1.18 Million
Q4 2020

Feb 17, 2021

SELL
$80.74 - $97.7 $191,999 - $232,330
-2,378 Reduced 14.76%
13,732 $1.19 Million
Q3 2020

Nov 13, 2020

BUY
$85.07 - $109.69 $6,890 - $8,884
81 Added 0.51%
16,110 $1.45 Million
Q2 2020

Aug 13, 2020

BUY
$74.18 - $108.93 $11,127 - $16,339
150 Added 0.94%
16,029 $1.67 Million
Q1 2020

May 15, 2020

SELL
$63.18 - $85.97 $66,212 - $90,096
-1,048 Reduced 6.19%
15,879 $1.16 Million
Q4 2019

Feb 14, 2020

SELL
$73.04 - $95.72 $9,349 - $12,252
-128 Reduced 0.75%
16,927 $1.48 Million
Q3 2019

Nov 14, 2019

BUY
$72.82 - $86.52 $1.24 Million - $1.48 Million
17,055 New
17,055 $1.27 Million
Q2 2019

Aug 13, 2019

SELL
$73.52 - $88.7 $205,782 - $248,271
-2,799 Closed
0 $0
Q1 2019

May 14, 2019

BUY
$63.56 - $88.17 $177,904 - $246,787
2,799 New
2,799 $241,000
Q3 2017

Nov 14, 2017

SELL
$109.15 - $138.27 $177,150 - $224,412
-1,623 Closed
0 $0
Q2 2017

Aug 14, 2017

BUY
N/A
1,623
1,623 $204,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $15.3B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track United Capital Financial Advisers, LLC Portfolio

Follow United Capital Financial Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of United Capital Financial Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on United Capital Financial Advisers, LLC with notifications on news.